Bioceltix SA GPW:BCX:
REPORTED ON FRIDAY Q3 NET LOSS AT 4.4 MLN ZLOTYS
Source text:
Further company coverage:
Bioceltix Q3 Net Loss At 4.4 Mln Zlotys
In the deck
Earlier from Bioceltix
- TFI PZU Funds Up Stake In Bioceltix To 15.75%
- Bioceltix Says EGM To Vote On Increase of Share Capital Via Issue Of O Series Shares
- Bioceltix's Shareholders Complete ABB Process
- Bioceltix Shareholders Start ABB For Sale Of Up To 577,785 Company Shares
Later from Bioceltix
- Bioceltix Gets GMP Certificate For Wroclaw Veterinary Medicine Facility
- BCX: Pioneering stem cell therapies for pets, with proven efficacy and major market expansion plans
- Bioceltix Signs Advisory Agreement For FDA Regulatory Support
- BCX: Advanced cell therapy pipeline, secured funding, and strengthened readiness for commercialization
- BCX: Strong cash position, regulatory progress, and major investments mark Q1 2026 pre-commercial phase
Follow Bioceltix into a list and get an email when it puts out news.
Follow Bioceltix